Prevention of urinary passage toxicity of oxazaphosphorines (Ifosfamide ,Cyclophosphamide, Trofosamide), in particular in high-risk patients with previous radiation therapy in the area of the lesser pelvis, cystitis with previous Ifosfamide, Cyclophosphamide or Trofosamide , urinary passage diseases in anamnesis.